- SEK206.18m
- -SEK60.82m
- SEK26.00m
Brief: Orexo Q3 EBIT SEK -98.5 Million
Brief: Orexo Completes First Preclinical Study Of Oral Semaglutide Tablet
Brief: Orexo Resolves To Carry Out Rights Issue Of SEK 250 Mln
Brief: Orexo Resubmits NDA For Izipry To FDA
Brief: Orexo Announces FDA Acceptance Of Investigational New Drug Application
Brief: Orexo US Gets Contract Modification From BARDA
Brief: Orexo Reaches Non-Binding Agreement In Principle To Settle Investigation By US Department Of Justice
Sweden's Orexo Q2 revenue falls, net loss widens on higher operating expenses
Brief: Orexo Q2 EBIT SEK -103.3 Million
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens
Brief: Orexo Reports Q1 Loss Of SEK 105.2 Million
Brief: Orexo Calls For Early Redemption Of Outstanding Senior Secured Social Bonds
Sweden's Orexo Q4 net earnings rise on Zubsolv sale
Brief: Orexo Q4 EBIT Loss At SEK 103.2 Mln
Brief: Orexo Q3 Revenue AT SEK 118.7 Mln, Guidance Unchanged